Pharmaceutical News

RSS

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Eisai Inc. (Headquarters: Woodcliff Lake, NJ; Chairman and CEO: Hajime Shimizu), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito) today announced that the U.S. Food and Drug Administration has accepted Eisai's New Drug Application for rabeprazole sodium extended-release 50 mg for the healing and maintenance of healing of erosive gastroesophageal reflux disease, and for the treatment of symptomatic GERD.

3 Jun 2010

Experts call on EU Parliament to ensure widespread benefits of nanomedicine

Experts from key EU projects united in Brussels at Nanomedicine in Europe today to deliver a strong message to the European Parliament that concerted and coordinated action is needed to ensure the widespread benefits offered by advances in nanomedicine are not squandered.

3 Jun 2010

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Three new oral blood-thinning drugs nearing approval by the Food and Drug Administration are more convenient than the standard drug Coumadin® because they do not require monthly visits to adjust doses.

2 Jun 2010

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced that it has signed an agreement to raise over $5 million by selling 2 million shares of equity to Crisnic Fund, S.A. based on a 15% discount from the volume weighted average price on the date the SEC declares the registration effective, as detailed in the 8-K being filed today.

2 Jun 2010

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets).

2 Jun 2010

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.

2 Jun 2010

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Aspirin may not be beneficial for young adults with diabetes

Experts are now recommending that low-dose aspirin therapy to prevent heart attacks be used somewhat more conservatively - that men younger than 50 and women younger than 60, who have diabetes but no other major risk factors, probably not use aspirin.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company's pharmaceutical products from the Greek market.

2 Jun 2010

Majority of poker players use performance enhancing drugs: Study

A Nova Southeastern University study recently presented at a national conference found that 80 percent of poker players around the world reported using drugs and other substances to enhance their performance in poker.

2 Jun 2010

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

Emerson Ecologics, LLC announces the debut of the first group of manufacturers to be awarded Partner status in the Emerson Quality Program(SM) (EQP). This one-of-a-kind quality assurance program for the nutritional supplements industry provides practitioners with manufacturer-specific quality and safety information to assist in confidently recommending the best products to patients.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

Plans to continue flu vaccination ban – intensive investigations ongoing

In the first quarter of this year nearly 300 children across Australia fell ill with fevers, vomiting and convulsions following administration of the seasonal flu vaccine.

2 Jun 2010

Rep. Dingell opposes proposal for drug reimportation

Rep. John Dingell, D-Mich., will stand in the way of a proposal by Sen. Byron Dorgan, D-N.D., to attach a drug reimportation amendment to Dingell's food safety bill, which Dingell said "could derail the whole food safety effort," The Hill reports. "Adding to the charged politics is the widespread assumption that the Obama administration, which has made food safety a priority, may intervene behind the scenes against the amendment.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

Prototype breast cancer vaccine shows promising results in mice

US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

Pharmaceutical News

FDA accepts Eisai's NDA for rabeprazole sodium extended-release 50 mg

Experts call on EU Parliament to ensure widespread benefits of nanomedicine

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Aspirin may not be beneficial for young adults with diabetes

Research findings advance the effort to develop AIDS vaccine

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

Majority of poker players use performance enhancing drugs: Study

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

Plans to continue flu vaccination ban – intensive investigations ongoing

Rep. Dingell opposes proposal for drug reimportation

FDA grants priority review status to Eisai's eribulin NDA

Prototype breast cancer vaccine shows promising results in mice

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News